3D Breast Cancer Specimen Imaging – The Future is Now
Breast cancer imaging results can be greatly improved upon with 3D specimen radiography, a new advance in breast cancer treatment offered exclusively by Kubtec.
Milford, CT, January 10, 2016 --(PR.com)-- Up until now, the analysis of breast cancers removed during surgery has been limited to two dimensional imaging, which affords an adequate yet relatively flat perspective. Breast cancer specimens, however, often contain tumors that radiate outward with long thin structures or spiculations, which must be removed entirely to obtain a clean margin and a positive outcome.
Research published by the New England Journal of Medicine shows that 20 to 40% of patients who opt for a lumpectomy after breast cancer detection must return for a second intervention due to lingering cancerous cells, which results in additional scarring and trauma. These disheartening results can be greatly improved upon with 3D specimen radiography, a new advance in breast cancer treatment offered exclusively by Kubtec, a Connecticut digital imaging company.
According to Vikram Butani, CEO of Kubtec, “3D specimen imaging is truly a game changer, as for the first time surgeons and radiologists will be able to clearly visualize the tumor and spiculations and not just the fiducials placed by the physician prior to the surgery based on the mammogram. This means that the radiologist and surgeon can have greater confidence that they have obtained clean margins, and have greater confidence that the patient will not be recalled for re-excision.”
Fear has motivated a growing number of women with breast cancer to initially opt for a mastectomy rather than a lumpectomy, and in some cases having both breasts removed, even if cancer has been detected in only one. Studies, however, show that this does not ensure a positive outcome. Research presented by radiation oncologist Dr. Benjamin Smith from the MD Anderson Cancer Center in Houston at the 2015 San Antonio Breast Cancer Symposium revealed that patients who underwent mastectomy and reconstruction had "nearly twice the risk" of complications in the two following years than patients who had a lumpectomy and radiation. These complications come at an average cost of $10,005, a seven fold increase as compared to a lumpectomy and whole-breast irradiation, which drops to $1,397.
In an effort to foster breast conservation and avoid the scarring and suffering that accompany mastectomies and re-excisions, 3D specimen imaging enables doctors to get it right the first time and allows patients to have greater confidence in their standard of care.
As Butani explains, “Rather than viewing the breast tissue in 2 dimensions, 3D imaging enables physicians to examine the specimen one thin layer at a time, in a sense traveling through the structure of the breast like flipping pages of a book. Fine details are more visible and are less likely to be hidden by overlapping tissue.”
This breakthrough in intraoperative breast cancer technology has yet to be fully embraced by the medical community, either out of unawareness of its existence or reliance on legacy 2D equipment for familiarity reasons. Yet for patients and doctors who strive to beat the odds and improve outcomes, 3D imaging is no longer the future; it is now.
To learn more about 3D specimen tomosynthesis, visit the Kubtec.com website.
About Kubtec®
Kubtec, a registered trademark of KUB Technologies, Inc., develops and manufactures digital X-ray systems for clinical and non-clinical applications, including low-dose neonatal imaging, specimen radiography, scientific research, forensic analysis, non-destructive testing, irradiation and more. Kubtec is ISO 9001 and ISO 13485 certified and complies with U.S., Canadian, and European requirements for radiation safety. Systems and manufacturer-trained support is available worldwide.
Twitter: Kubtec
Facebook: Kubtec
LinkedIn: Kubtec
Research published by the New England Journal of Medicine shows that 20 to 40% of patients who opt for a lumpectomy after breast cancer detection must return for a second intervention due to lingering cancerous cells, which results in additional scarring and trauma. These disheartening results can be greatly improved upon with 3D specimen radiography, a new advance in breast cancer treatment offered exclusively by Kubtec, a Connecticut digital imaging company.
According to Vikram Butani, CEO of Kubtec, “3D specimen imaging is truly a game changer, as for the first time surgeons and radiologists will be able to clearly visualize the tumor and spiculations and not just the fiducials placed by the physician prior to the surgery based on the mammogram. This means that the radiologist and surgeon can have greater confidence that they have obtained clean margins, and have greater confidence that the patient will not be recalled for re-excision.”
Fear has motivated a growing number of women with breast cancer to initially opt for a mastectomy rather than a lumpectomy, and in some cases having both breasts removed, even if cancer has been detected in only one. Studies, however, show that this does not ensure a positive outcome. Research presented by radiation oncologist Dr. Benjamin Smith from the MD Anderson Cancer Center in Houston at the 2015 San Antonio Breast Cancer Symposium revealed that patients who underwent mastectomy and reconstruction had "nearly twice the risk" of complications in the two following years than patients who had a lumpectomy and radiation. These complications come at an average cost of $10,005, a seven fold increase as compared to a lumpectomy and whole-breast irradiation, which drops to $1,397.
In an effort to foster breast conservation and avoid the scarring and suffering that accompany mastectomies and re-excisions, 3D specimen imaging enables doctors to get it right the first time and allows patients to have greater confidence in their standard of care.
As Butani explains, “Rather than viewing the breast tissue in 2 dimensions, 3D imaging enables physicians to examine the specimen one thin layer at a time, in a sense traveling through the structure of the breast like flipping pages of a book. Fine details are more visible and are less likely to be hidden by overlapping tissue.”
This breakthrough in intraoperative breast cancer technology has yet to be fully embraced by the medical community, either out of unawareness of its existence or reliance on legacy 2D equipment for familiarity reasons. Yet for patients and doctors who strive to beat the odds and improve outcomes, 3D imaging is no longer the future; it is now.
To learn more about 3D specimen tomosynthesis, visit the Kubtec.com website.
About Kubtec®
Kubtec, a registered trademark of KUB Technologies, Inc., develops and manufactures digital X-ray systems for clinical and non-clinical applications, including low-dose neonatal imaging, specimen radiography, scientific research, forensic analysis, non-destructive testing, irradiation and more. Kubtec is ISO 9001 and ISO 13485 certified and complies with U.S., Canadian, and European requirements for radiation safety. Systems and manufacturer-trained support is available worldwide.
Twitter: Kubtec
Facebook: Kubtec
LinkedIn: Kubtec
Contact
Kubtec
Mark Lugris
203-364-8544
kubtec.com
Mark Lugris
203-364-8544
kubtec.com
Contact
Categories